Zanamivir (1 brand name, 1 dosage form, 1 route)
Available dosage forms: POWDER.
Routes of administration: INHALATION.
Brand Names
- RELENZA
Contraindications
RELENZA is contraindicated in patients with history of allergic reaction to any ingredient of RELENZA, including milk proteins [see Warnings and Precautions (5.2), Description (11)].
Adverse Reactions
The following adverse reactions are discussed in greater detail in other sections of the labeling: •Bronchospasm [see Warnings and Precautions (5.1)]. •Safety information in patients with underlying airways disease [see Warnings and Precautions (5.1)]. •Allergic-like reactions [see Warnings and Precautions (5.2)].
Drug Interactions
The concurrent use of RELENZA with live attenuated influenza vaccine (LAIV) intranasal has not been evaluated. However, because of potential interference between these products, LAIV should not be administered within 2 weeks before or 48 hours after administration of RELENZA, unless medically indicated. The concern about possible interference arises from the potential for antiviral drugs to inhibit replication of live vaccine virus. Trivalent inactivated influenza vaccine can be administered at any time relative to use of RELENZA [see Microbiology (12.4)].
Mechanism of Action
Zanamivir is an antiviral drug with activity against influenza virus [see Microbiology (12.4)].
Overdosage
Reports of overdosage from administration of RELENZA have been received during postmarketing experience. The reported clinical signs or symptoms were similar to those observed with therapeutic doses of RELENZA and the underlying disease. As zanamivir has a low molecular weight, low protein binding, and small volume of distribution, it is expected to be removed by hemodialysis.